- Home
- ORMP vs LNSR Comparison
ORMP vs LNSR Comparison
Compare ORMP & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | LNSR |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 142.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORMP | LNSR |
|---|---|---|
| Price | $3.14 | $11.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 272.7K | 48.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | $2,000,000.00 | ★ $59,141,000.00 |
| Revenue This Year | N/A | $19.55 |
| Revenue Next Year | N/A | $35.89 |
| P/E Ratio | $2.96 | ★ N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $1.82 | $7.13 |
| 52 Week High | $3.19 | $17.31 |
Technical Indicators
Market Signals| Indicator | ORMP | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 74.34 | 60.61 |
| Support Level | $2.66 | $11.00 |
| Resistance Level | $2.84 | $11.63 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | 0.03 | 0.21 |
| Stochastic Oscillator | 80.89 | 93.43 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.